# Advanced Technology-Core

> **NIH NIH P30** · WASHINGTON UNIVERSITY · 2024 · $66,735

## Abstract

Project Summary Advanced Technology Core (ATC)
As part of the Midwest D-CFAR, the Advanced Technology Core (ATC) will develop, support, and enhance the
impact of basic and translational HIV investigators to accelerate progress in priority areas of HIV research and
translate research discoveries into improvements in human health. The research enterprise at Washington
University (WashU) and Saint Louis University (SLU) is an enormous asset to our growing HIV-investigator
community. WashU and SLU received $658.1 million in funding from the National Institutes of Health in 2022.
They have a wealth of state-of-the-art core services and a large group of highly trained, highly successful
investigators working in disciplines that intersect HIV priority areas, such as microbial pathogenesis,
immunology, neuroscience, and inflammatory, metabolic, and cardiovascular diseases. Our outstanding HIV
basic and translational scientists are poised for growth, and the ATC will leverage the scientific resources at
WashU/SLU and bring together experienced and early-career HIV-focused researchers and non-HIV
investigators to drive innovative discovery and translation. The ATC will be led by accomplished basic and
translational science investigators and institutional leaders, Drs. Liang Shan and George Kyei. The ATC will
contribute to the overall D-CFAR objectives through the establishment of three new units: the Consultation
Service Unit (CSU), the Virology Research Unit (VRU), and the Technology Accessibility Unit (TAU).
These units will: (1) provide consultation services to foster mentorship and collaborative, multidisciplinary HIV-
focused basic research on HIV reservoirs, cure strategy, and HIV-associated comorbidities and coinfections,
(2) provide training, reagents, and experimental services for basic and translational HIV research, and (3)
provide cost-effective access to state-of-the-art technology in sequencing, imaging, immunophenotyping, and
drug discovery. Emerging HIV investigators will be eligible for preferred rates, pilot funds, and microgrants to
access cutting-edge technology and ATC services. In addition, we will enhance basic and translational
research by providing researchers with access to highly experienced investigators conducting translational
research and clinical trials, thereby promoting the development and optimization of novel interventions. Finally,
by engaging the sizeable non-HIV-focused research base, the ATC will bring new ideas and approaches to
studies focused on HIV cure and HIV-associated comorbidities and coinfections. In summary, the ATC will
reduce roadblocks and expand the reach of HIV investigation at WashU and SLU to contribute to the end of
the HIV epidemic.

## Key facts

- **NIH application ID:** 10898386
- **Project number:** 1P30AI176532-01A1
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** LIANG SHAN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $66,735
- **Award type:** 1
- **Project period:** 2024-05-10 → 2029-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10898386

## Citation

> US National Institutes of Health, RePORTER application 10898386, Advanced Technology-Core (1P30AI176532-01A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10898386. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*